铜绿假单胞菌制剂经胸腔注入治疗恶性胸腔积液临床的的疗效观察.docVIP

铜绿假单胞菌制剂经胸腔注入治疗恶性胸腔积液临床的的疗效观察 　　[摘要] 目的:观察铜绿假单胞菌制剂经胸腔注入治疗恶性胸腔积液的临床疗效。方法:将84例恶性胸腔积液患者按入院先后顺序随机分组, 治疗组43例给予铜绿假单胞菌制剂胸腔注入治疗,对照组41例给予顺铂胸腔注入治疗,对临床疗效及毒副作用进行比较观察。结果:治疗组有效率明显高于对照组(P0.05)。在毒副作用方面, 除了治疗组中7例(16.3%)出现轻度发热,9例(18.6%)出现轻度胸痛, 其他方面毒副作用明显少于对照组(P0.05)。结论:铜绿假单胞菌制剂经胸腔注入治疗恶性胸腔积液是一种安全有效的治疗手段。 　　[关键词] 铜绿假单胞菌;恶性胸腔积液;顺铂 　　[中图分类号]R730.5 [文献标识码]B [文章编号]1673-7210(2010)04(a)-103-02 　　 　　Clinical observation of PA-MSHA administration through intrapericardial infusion in the treatment of m alignant pleural effusion 　　ZHU Libo , WANG Yingjie,LIU Qingyuan 　　(Liaoning Cancer Hospital, Shenyang 110042, China) 　　[Abstract] Objective: To observe the clinical effect of PA-MSHA administration through intrapericardial infusion in the treatment of m alignant pleural effusion. Methods: 84 cases of m alignant pleural effusion patients were randomly divided into treatment group (43 cases) and control group (41 cases). In the treatment group, the patients received PA-MSHA administration through intrapericardial infusion; in the control group, the patients received Cisplatin through intrapericardial infusion. We evaluated the clinical effect, side effect and toxicity. Results: The response rate of the treatment group was higher than that of control group (P0.05). The patients in the treatment group occurred lower side effects and toxicity than that of in the the control group (P0.05), except that 7 cases(16.3%) occurred fever and 9 cases(18.6%) occurred chest pain. Conclusion: PA-MSHA administration through intrapericardial infusion in the treatment of m alignant pleural effusion is an effective, safe therapeutic way. 　　[Key words] PA-MSHA; Cisplatin; M alignant pleural effusion 　　 　　恶性胸腔积液是恶性肿瘤常见的并发症,常提示肿瘤进入晚期。由于机体状况很差,很多晚期恶性肿瘤患者已不能耐受较为强烈的放疗和全身化疗。既往临床上常用的方法是胸腔内注入抗癌药物或化学硬化剂进行治疗,但疗效不满意,故寻找一种更为有效控制恶性胸腔积液的方法就显得尤为重要。为此,2006年6月～2008年1月我院收治84例恶性胸腔积液患者,采用铜绿假单胞菌制剂胸腔注入治疗43例,顺铂胸腔注入治疗41例,两组比较,前者疗效满意,现报道如下: 　　1 资料与方法 　　1.1 一般资料 　　患者按入院先后顺序随机分为治疗组43例(铜绿假单胞菌制剂胸腔注入)和对照组41例(顺铂胸腔注入)。治疗组43例,男25例,女18